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Summary The levels of tumour-associated trypsin inhibitor (TATI), CA 125 and CEA were measured in
ovarian cyst fluids from 21 patients. TATI in cyst fluid was immunologically and physicochemically similar to
the peptide originally isolated from the urine of a patient with ovarian cancer. Mucinous cysts contained
significantly higher levels of TATI than did serous cysts. Immunohistochemically TATI was localized in the
apical parts of cells of mucinous ovarian cysts. These results suggest that this tumour-associated peptide is
actually produced by a tumour. Like TATI, CEA occurred at higher concentrations in mucinous than in
serous cyst fluids, whereas CA 125 was found in higher concentrations in serous than in mucinous cyst fluids.
The concentrations of these tumours markers in cyst fluids did not correlate with circulating levels of the
same markers. In spite of the very high levels of all these tumour markers in benign cyst fluids, serum levels
were normal or only slightly elevated. Clearly elevated serum levels occurred only in patients with malignant
tumours. Cyst fluid levels of these tumour markers could not be used to distinguish between benign and
malignant tumours.
Tumour-associated trypsin inhibitor (TATI) was identified
and isolated from the urine of a patient with ovarian cancer
(Stenman et al., 1982). The N-terminal amino acid sequence
of TATI was found to be identical to that of pancreatic
secretory trypsin inhibitor (PSTI) (Huhtala et al., 1982)
initially isolated from bovine pancreas (Kazal et al., 1948).
In immunodiffusion TATI and PSTI reacted identically
(Halila et al., 1985). PSTI is a 6,000 dalton polypeptide
occurring in pancreatic secretion of all mammals studied. It
has been suggested that the role of PSTI in pancreas is to
prevent premature or accidental trypsinogen activation thus
hindering autodigestion of the gland (Fritz et al., 1967).
Increased excretion of TATI into urine has been observed in
patients with gynaecological malignancies (Huhtala et al.,
1983). This is not caused by pancreatic involvement, but
direct evidence for production of TATI by the tumour of
cancer patients has not been shown. Extrapancreatic
production of TATI has been demonstrated; pancreatecto-
mized patients have normal levels of TATI (Halila et al.,
1985) and it occurs in e.g. human seminal plasma (Huhtala,
1984).
Ovarian cyst fluid contains tumour-associated antigens.
Carcinoembryonic antigen (CEA) levels are elevated in
mucinous ovarian cysts (van Nagell et al., 1975) and CA 125
has been found at high concentrations in cyst fluids from
epithelial ovarian cystic tumours, both benign and malignant
(de Bruijn et al., 1986). In this study the concentrations of
TATI, CA 125 and CEA were studied in benign and
malignant ovarian cyst fluids. The tissue expression of TATI
in cystic ovarian tumours was studied by immunohisto-
chemistry.
Materials and methods
Samples
Cyst fluid was obtained during operation from 21 patients
with ovarian cystic tumours. These included 10 benign
mucinous cystadenomas, I borderline and I malignant
mucinous tumour; 4 benign serous cystadenomas, 1
borderline and 4 malignant serous tumours. Serum samples
were available from 15 of these patients. Cyst fluid and
serum samples were stored at -20'C until assayed. Serum
and urine with a high content of TATI were obtained from
patients with advanced ovarian cancer. TATI was purified
from urine of a patient with ovarian cancer (Huhtala et al.,
1982).
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Histological specimens
Samples from 58 ovarian cystic tumours were studied. These
included 13 benign mucinous cystadenomas, 7 borderline and
7 malignant mucinous tumours; 19 benign serous cyst-
adenomas, 8 borderline and 4 malignant serous tumours.
The samples were formalin-fixed and paraffin-embedded
surgical specimens, stored for 10 month to 10 years.
Radioimmunoassays
The concentration of TATI was measured by radioimmuno-
assay (RIA) as described previously (Stenman et al., 1982).
Separation of bound and free antigen was achieved by the
addition of 100,l of donkey anti-rabbit IgG bound to
cellulose particles (Sac-Cel, Wellcome Reagents Limited,
Beckenham, England). After incubation for 30min, the
particles were sedimented by centrifugation at 3,000g for
5min. The sensitivity of the assay was 0.5pg -1. For cyst
fluid samples the sensitivity was Spgl-1 because these were
analyzed at a 10-fold or greater dilution. The mean (+2s.d.)
level of TATI in serum is 11.3 (±8.4)gl- 1, (Stenman et al.,
1982). The immunoreactivity of serial dilutions of mucinous
cyst fluid was compared with that of serial dilutions of
purified TATI.
The CA 125 immunoradiometric assay was performed
according to the manufacturer's instructions (Centocor,
Malvern, Pennsylvania, USA). Cyst fluid and serum samples
were assayed both undiluted and appropriately diluted in
order to avoid the hook effect occurring at CA 125
concentrations higher than 3,000-4,000 U ml (Klug et al.,
1984; Heinonen et al., 1984). The sensitivity of the assay was
7U ml -. Normal serum levels are below 35 Uml (Bast et
al., 1983).
Cyst fluid and serum CEA levels were measured using an
immunoradiometric kit based on monoclonal antibodies
(Abbott Laboratories, North Chicago, Illinois, USA). The
sensitivity of the assay was 3pg -1, which is also the cut-off
level for normal serum.
Gelfiltration
Gel filtration was performed on a 1.5 x 83 cm Sephadex G-50
column (Pharmacia Fine Chemicals, Uppsala, Sweden) in
0.1 M ammonium acetate buffer, pH 4.35. One ml samples
were applied to the column. Ovalbumin (Mr 65,000), soybean
trypsin inhibitor (Mr 18,000), aprotinin (Mr 6,000) (Bayer
AG, Leverkusen, FRG) and angiotensin (Mr 700) (Ciba-
Geigy, AG, Basel, Switzerland) were used as molecular
weight markers. The flow rate was 16ml h i and fractions of
1.8 ml were collected, lyophilized and tested for TATI
immunoreactivity by radioimmunoassay. The eluates were
monitored for absorbance at 280 nm. The fractions
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containing imimlunoreactive TATI were pooled and further
analysed by reverse phase chromatography and RIA.
Reverse phase high pressure liquid chromatography
High performance liquid chromatography was carried out on
a Varian 5020 chromatograph (Varian Instruments, Walnut
Creek, CA, USA) using a reverse phase column (Spherisorb
RP-8, particle size 5 pum, column size 4 x 250mm). The
column was equilibrated with 0.1 mol 1- 1 ammonium acetate,
pH4.35, containing 10% acetonitrile. Elution was achieved
by increasing the concentration of acetonitrile to 55% in
25min. The flow rate was lmlmin-i and fractions of 1ml
volume were collected. Immunoreative TATI was determined
by RIA after dissolving the lyophilized fractions in 0.3ml of
RIA buffer.
Immunodiffusion
Immunodiffusion was performed on 10 x 1O cm plates using
0.9% agar in phosphate-buffered. (10 m mol l-1, pH 7.4)
saline (150mmoll-1) (PBS) containing 4% polyethylene
glycol 6,000 (Fluka AG, Buchs, Switzerland). Ten-,ul samples
of cyst fluid from a benign mucinous cyst, urine of a patient
with ovarian cancer and antiserum against TATI were used
and the immunoprecipitates were observed after 12-24h.
Staining procedure
Five pm thick sections were deparaffinized, hydrated and
treated with 0.4% pepsin (2,500 FIP-Ug- 1, Merck,
Darmstadt, West Germany) in 0.01 N HCI for 1 h at 37°C.
Pepsin pretreatment has been shown to enhance the TATI
staining (Haglund et al., 1986). An indirect immuno-
peroxidase staining technique was used. The sections were
incubated in 0.5% hydrogen peroxide in methanol to block
endogenous peroxidase, and then successively treated with
non-immune swine serum (1:20), rabbit antiserum to TATI
(1:20) and swine anti-rabbit peroxidase conjugate (Dako,
Copenhagen, Denmark) (1: 100). The sections were finally
exposed to 3-amino-9-ethyl carbazole and hydrogen
peroxide. Washing with PBS followed each step. All sections
were counterstained with haematoxylin. Staining with non-
immune rabbit serum and with PBS were used as negative
controls. A positive specimen of normal pancreas was used
as a positive control in each series.
Statistical analyses
Statistical analyses were performed using the unpaired
Student's t-test. Linear regression analysis was used to study
the correlation between cyst fluid levels of various tumour
markers.
Results
TATI in mucinous and serous cystfluids
All mucinous cyst fluids contained high concentrations of
immunoreactive TATI (median 9,010pgl-1, range 760-
42,000 pg1 1) (Table I). In serous cyst fluids the median
TATI concentration was 15 pg1 1. The range was <5-
407 pgl-1), which is similar to that in normal serum. The
concentration in mucinous cyst fluids was significantly higher
than in serous cyst fluids (P=0.015). No significant
differences were found in the cyst fluid TATI levels between
benign and borderline or malignant cysts.
Comparison of serum and cyst fluid levels of TATI in
various patients demonstrated no statistically significant
correlation. Serum levels of TATI were normal in most
patients with mucinous cysts in spite of about 1,000-fold
levels in cyst fluid compared to serum. Only one patient (No.
4, Table I) with the highest cyst fluid level had a moderately
elevated serum level. A clearly elevated serum level was
observed in a patient with malignant serous cystadenoma
(No. 20, Table I) containing a similar cyst fluid level.
Immunochemical and chromatographic characterization of
TATI
In radioimmunoassay, serial dilutions of cyst fluid
containing TATI gave a dose-response curve parallel to that
of TATI purified from the urine of a patient with ovarian
cancer (Figure 1). In gel chromatography, TATI of cyst fluid
eluted in the same volume as TATI from urine of a patient
with ovarian cancer, corresponding to molecular weight of
6 kDa (Figure 2). In reverse phase chromatography, the
retention times were also similar (Figure 3). By immuno-
diffusion, TATI in mucinous cyst fluid and in urine from a
patient with ovarian cancer showed complete identity with
purified TATI (not shown).
Immunohistochemical stainingfor TATI
Mucinous tumours Eleven out of 13 (85%) benign mucinous
cystadenomas expressed TATI, whereas only 3 out of 7
(43%) borderline mucinous tumours and 2 out of 7 (29%)
mucinous cystadenocarcinomas were positive for TATI. The
Table I Levels of TATI, CA 125 and CEA in ovarian cyst fluids with the corresponding serum values
Cystfluid levels Serum levels
Patient TATI CA 125 CEA S-TATI S-CA 125 S-CEA
no. Histology ,ugl Uml I pgl - I lgl - UmlI - ig 1l
1 benign mucinous 4,585 2,786 800 NT NT NT
2 benign mucinous 9,140 44,000 1,750 NT 6 <3
3 benign mucinous 15,300 45,550 11,000 NT NT NT
4 benign mucinous 42,000 567 6,800 42 32 <3
5 benign mucinous 1,283 19,185 8,525 16 23 <3
6 benign mucinous 9,840 2,630 1,075 NT 54 NT
7 benign mucinous 760 8,413 21,750 13 68 <3
8 benign mucinous 1,754 9,035 19,100 NT NT NT
9 benign mucinous 12,350 34,300 2,250 NT NT NT
10 benign mucinous 8,877 NT NT 14 NT <3
11 borderline mucinous 1,882 1,564 3,200 9 39 <3
12 malignant mucinous 15,010 4,250 26,300 19 <7 <3
13 benign serous <5 16,500 <3 11 23 <3
14 benign serous 18 117,400 <3 NT NT NT
15 benign serous <5 279,700 435 13 20 <3
16 benign serous 16 27,700 4 11 56 <3
17 borderline serous 15 12,500 <3 15 35 <3
18 malignant serous 407 38,700 <3 NT NT NT
19 malignant serous 17 125,000 <3 NT NT NT
20 malignant serous 145 4,045 <3 113 900 NT
21 malignant serous 7 42,020 <3 10 169 <3
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Figure I Dose-response curves of mucinous ovarian cyst fluid
(E- ) and of purified TATI ( * ) in radioimmunoassay.
The curves are parallel indicating immunological identity.
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Figure 2 Gel filtration of mucinous cyst fluid ( nF ) and of
purified TATI ( * ). The concentration of TATI in the
fractions was measured by radioimmunoassay.
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Figure 3 Comparison of TATI in mucinous cyst fluid ( -1 ),
in serum from a patient with ovarian cancer ( * ) and of
purified TATI ( * ) by high performance liquid chromato-
graphy with a reverse phase column.
positivity was predominantly seen in the apical parts of the
cells (Figure 4). The mucin of intracellular vacuoles and
mucus inside the cysts was often clearly positive. In part of
the specimens the positivity was only focal, especially in
cystadenocarcinomas where only occasional cells stained.
Serous tumours All benign, borderline and malignant
ovarian serous tumours were negative for TATI.
Cyst fluid levels of CA 125 and CEA
All cyst fluids studied contained high levels of CA 125
antigen as compared with normal serum levels. The levels in
Figure 4 Immunoperoxidase staining of a benign 11U1IHIOlIS
ovarian cystadenoma with antibodies against TATI
counterstained with haematoxylin ( x 600).
serous cyst fluids (median 38,700 U ml 1, range 4,045-
279,700 U ml -1) were significantly higher (P =0.047) than
those in mucinous cyst fluids (median 6,332 Uml- 1, range
567-45,550Uml-1). No differences were found in the levels
between benign and borderline or malignant tumours. The
cyst fluid levels of CA 125 did not correlate with the corres-
ponding serum levels.
High levels of CEA were found in all mucinous cyst fluids
(median 6,800gl-1, range 800-26,300jgl-1). The levels
were significantly higher (P=0.011) than in the serous cyst
fluids (median <3pg1-1, range <3-435ugl -1). No
differences were found in the levels between benign and
borderline or malignant cysts. The high cyst fluid levels did
not cause elevated serum levels, which all were below the
detection limit of the assay.
Comparison of cyst fluid levels of TATI, CA 125 and CEA
There was a weak positive correlation between TATI and
CEA in the mucinous (r=0.48) and in the serous (r=0.25)
tumours. Between TATI and CA 125 there was a weak
negative correlation both in mucinous (r= -0.33) and serous
(r= -0.20) tumours. A similar weak negative correlation
was found between CEA and CA 125 (r= -0.19; -0.35,
respectively).
Discussion
The epithelium of mucinous human ovarian cysts was found
to express TATI, which also occurred at high concentrations
in mucinous cyst fluids. TATI in cyst fluid was immuno-
chemically and chromatographically indistinguishable from
TATI isolated from the urine of a patient with ovarian
cancer. The median concentration of TATI in mucinous cyst
fluid was about 600-fold compared to normal serum levels.
This together with the strong immunohistochemical staining
indicates, that TATI is synthesized by the ovarian cyst tissue.
The tissue expression of TATI in mucinous but not in serous
cystic tumours is analogous with the findings in cystic
tumours of the pancreas, which they histologically resemble.
Immunohistochemical results suggest that ovarian mucinous
cystic tumours, like their pancreatic counterparts (Haglund
et al., 1986), seem to lose their capacity of expressing TATI
with increasing degree of malignancy.
TATI has previously been shown to occur in cancer tissue
extracts (Stenman et al., 1982). The present results provide
more direct evidence for production of this tumour-
associated peptide by tumour cells. Production of TATI is
not specific for tumour cells. It may be elevated in severe
infections (Huhtala et al., 1983), after major injury (Ogawa
et al., 1985) and in biliary obstruction (Haglund et al., 1986).
This suggests, that TATI can also be produced by other than
tumour cells, possibly as a reaction to tissue destruction.
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Tumour cells are known to produce proteases. As a result
of increased protease activity, expression of protease
inhibitors is also increased (Strauli, 1980). The role of TATI
as a protease inhibitor is therefore a possible explanation to
the increased levels in cancer patients, although the origin of
TATI in this case is not known. Recently another
explanation has been offered. An endothelial cell growth
factor isolated from a human hepatoma cell line was shown
to be identical to TATI on the basis of its amino acid
sequence (McKeehan et al., 1986). These findings along with
the present finding of high concentrations of TATI in
mucinous ovarian cystic tumours focus the interest on a
possible role of this in normal and malignant growth.
OC 125, the monoclonal antibody on which the CA 125
assay is based, was originally prepared by immunization of
mice with a serous ovarian cystadenocarcinoma cell line
(Bast ct al., 1981). In our study, the highest cyst fluid levels
were found in serous tumours, but high levels were also
measured in mucinous tumours, although these tumours
have been found not to stain immunohistochemically with
the OC 125 antibody (Kabawat et al., 1983). The median
CA 125 level of all cyst fluids studied was about 1,000-fold
compared with normal serum levels, suggesting local
synthesis by the tumour.
In accordance with earlier findings (van Nagell et al.,
1975; Kraly et al., 1984; Knight et al., 1986; Tohya et al.,
1986) we found high levels of CEA in mucinous but not in
serous ovarian cyst fluids. This might be caused by the fact
that both of them are associated with gastrointestinal
malignancies (Haglund et al., 1986) and that mucinous
tumours of the ovary resemble gastrointestinal structures.
Mucinous ovarian cyst fluid has also been found to contain
other antigens in common with gastric mucosa (Nairn et al.,
1971; Bara et al., 1977).
TATI and CEA were associated with mucinous cyst fluids,
whereas higher levels of CA 125 were found in serous cyst
fluids. However, none of these tumour markers could
distinguish between benign or malignant tumours on the
basis of their cyst fluids levels. In spite of very high levels of
all these tumour markers in both malignant and benign cyst
fluids, only malignant tumours were associated with clearly
elevated serum levels. Thus factors other than the level
within the tumour determine whether the serum level
becomes increased. It is known that loss of basement
membrane integrity (e.g. laminin and type IV collagen) is
typical of malignant epithelial cells (Liotta et al., 1983). A
possible explanation for the elevation of serum levels of these
antigens in patients with malignant, but not benign tumours
might be the disruption of the basement membranes in
malignant tumours.
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